Abstract
Vasopressin is reported to enhance learning and memory in animal models. In 9 Down's syndrome patients DDAVP, a vasopressin derivative, was administered for 10 days, 40 μg per day, in a double-blind randomized crossover design. A visual-verbal paired associate learning test showed a not significant tendency for benefit with DDAVP. Word List memory was not improved with DDAVP treatment.
Original language | English |
---|---|
Pages (from-to) | 143-147 |
Number of pages | 5 |
Journal | Journal of Neural Transmission |
Volume | 60 |
Issue number | 2 |
DOIs | |
State | Published - 1 Jun 1984 |
Externally published | Yes |
ASJC Scopus subject areas
- Neurology
- Clinical Neurology
- Psychiatry and Mental health
- Biological Psychiatry